成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Pioglitazone

別名: AD-4833, U 72107 中文名稱：吡格列酮

Pioglitazone是一種選擇性過氧化物酶體增殖物激活受體γ (PPARγ) 激動劑， 用于治療糖尿病。是全長hPPARα的弱激活劑，對全長hPPARδ沒有作用。

Pioglitazone Chemical Structure

Pioglitazone Chemical Structure

CAS: 111025-46-8

規(guī)格 價格 庫存 購買數(shù)量
10mM (1mL in DMSO) 1056.72 現(xiàn)貨
10mg 789.99 現(xiàn)貨
50mg 1372.45 現(xiàn)貨
200mg 3033.76 現(xiàn)貨
1g 7944.3 現(xiàn)貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn
免費分裝
免費預溶

Pioglitazone相關(guān)產(chǎn)品

相關(guān)信號通路圖

PPAR Signaling Pathways

PPAR信號通路圖

細胞實驗數(shù)據(jù)示例

細胞系 實驗類型 給藥濃度 孵育時間 活性描述 文獻信息
HEK293T Function assay 1 uM 24 hrs Partial agonist activity at human PPARgamma-LBD expressed in HEK293T cells assessed as induction of receptor transactivation at 1 uM after 24 hrs by luciferase reporter gene assay 21030263
HEK293 Function assay 10 uM 24 hrs Transactivation of PPAR-gamma (unknown origin) expressed in HEK293 cells at 10 uM after 24 hrs by luciferase reporter gene assay 24890090
THP1 Function assay 10 uM 24 hrs Upregulation of ABCA1 mRNA expression in human THP1 cells at 10 uM after 24 hrs by qPCR method relative to control 27220065
THP1 Function assay 10 uM 24 hrs Upregulation of ABCG1 mRNA expression in human THP1 cells at 10 uM after 24 hrs by qPCR method relative to control 27220065
PC3 Function assay 50 uM 24 hrs Increase in p21(WAF1) protein expression in human PC3 cells at 50 uM incubated for 24 hrs by Western blot analysis 28395220
MDA-MB-231 Function assay 50 uM 24 hrs Increase in p21(WAF1) protein expression in human MDA-MB-231 cells at 50 uM incubated for 24 hrs by Western blot analysis 28395220
SCC15 Cytotoxicity assay 50 uM 24 hrs Cytotoxicity against human SCC15 cells transfected with PPARalpha siRNA assessed as reduction in cell viability at 50 uM after 24 hrs by resazurin reduction assay 29031063
SCC15 Cytotoxicity assay 50 uM 24 hrs Cytotoxicity against human SCC15 cells transfected with PPARbeta siRNA assessed as reduction in cell viability at 50 uM after 24 hrs by resazurin reduction assay 29031063
3T3L1 Function assay 10 uM 24 hrs Agonist activity at PPARgamma in mouse 3T3L1 cells assessed as increase in AP1 mRNA expression at 10 uM after 24 hrs by SYBR green dye based RT-PCR analysis 30594432
3T3L1 Function assay 10 uM 24 hrs Agonist activity at PPARgamma in mouse 3T3L1 cells assessed as increase in CD36 mRNA expression at 10 uM after 24 hrs by SYBR green dye based RT-PCR analysis 30594432
3T3L1 Function assay 10 uM 24 hrs Agonist activity at PPARgamma in mouse 3T3L1 cells assessed as increase in Glut4 mRNA expression at 10 uM after 24 hrs by SYBR green dye based RT-PCR analysis 30594432
3T3L1 Function assay 10 uM 24 hrs Agonist activity at PPARgamma in mouse 3T3L1 cells assessed as increase in adiponectin mRNA expression at 10 uM after 24 hrs by SYBR green dye based RT-PCR analysis 30594432
K562-IMA[r] Function assay 10 uM 72 hrs Induction of sensitization to imatinib-induced cytotoxicity in imatinib-resistant human K562-IMA[r] cells assessed as induction of cell death at 10 uM after 72 hrs in presence of 1 uM imatinib by propidium iodide/Triton-X100 dye based FACS analysis 31648125
3T3L1 Function assay 100 umol/L Increase in PPARgamma mRNA levels in mouse 3T3L1 cells at 100 umol/L by RT-PCR 20392645
HepG2 Function assay 30 uM Binding affinity to NAF1 (unknown origin) expressed in human HepG2 cells assessed as inhibition of mitochondrial respiration at 30 uM 30770154
HepG2 Function assay 30 uM Binding affinity to NAF1 in human HepG2 cells assessed as inhibition of mitochondrial respiration at 30 uM 30770154
Cos7 Function assay 14 hrs Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay, EC50=0.3μM 20307981
CHO Function assay 24 hrs Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay, EC50=0.39μM 21377875
HepG2 Function assay 20 hrs Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay, EC50=0.57μM 22341573
HEK293 Function assay 18 hrs Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay, EC50=0.8μM 23102891
THP1 Antiinflammatory assay 1 hr Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA, IC50=18.84μM 23811092
THP1 Antiinflammatory assay 2 hrs Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA, IC50=18.6μM 24531227
HEK293 Function assay 18 hrs Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay, EC50=0.21μM 25333853
COS7 Function assay 42 hrs Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay, EC50=0.5μM 27560282
COS7 Function assay 42 hrs Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay, EC50=0.32μM 27569195
COS7 Function assay 42 hrs Transactivation of Gal4 fused human PPARgamma LBD expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay, EC50=0.38μM 27918994
HEK293 Function assay 24 hrs Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay, EC50=1.1μM 28465099
HEK293 Function assay 4 hrs Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay, IC50=22μM 28465099
HepG2 Function assay 24 hrs Agonist activity at PPARgamma in human HepG2 cells assessed as activation of PPRE incubated for 24 hrs by dual luciferase reporter gene assay, EC50=0.24μM 30001846
HEK293BENA Function assay 24 hrs Transactivation of GAL4-fused human PPARgamma transfected in HEK293BENA cells after 24 hrs by steady glo-luciferase reporter gene assay, EC50=2.053μM 30351933
HEK293 Function assay 18 hrs Transactivation of human full length PPARgamma expressed in HEK293 cells after 18 hrs by luciferase reporter gene based luminescence assay, EC50=0.1μM 30362739
293H Function assay 16 hrs Transactivation of GAL4-DBD fused human PPARgamma ligand binding domain expressed in UAS-bla HEL 293H cells preincubated for 16 hrs followed by FRET substrate addition and measured after 2 hrs by TR-FRET assay, EC50=0.098μM 30429097
stem cells Function assay 5 days Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in adiponectin production measured on day 5 in presence of IDX by ELISA, EC50=0.35μM 30672698
HEK293T Function assay 18 hrs Transactivation of full length human PPARgamma2 expressed in HEK293T cells co-expressing PPRE after 18 hrs by luciferase reporter gene assay, EC50=0.25μM 30676741
HEK293T Function assay 18 hrs Transactivation of chimeric Gal4 yeast DBD fused-PPARgamma LBD (unknown origin) expressed in HEK293T cells co-expressing PPRE after 18 hrs by luciferase reporter gene assay, EC50=0.35μM 30676741
COS7 Function assay 39 hrs Transactivation of Gal4-fused human PPARgamma transfected in COS7 cells co-transfected with pGAL5-TK-pGL3 and pRennilla-CMV incubated for 39 hrs by dual luciferase reporter assay, EC50=1.4μM 31648125
CV-1 Function assay In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells, EC50=0.69μM 8576907
3T3-L1 Function assay Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells, EC50=0.16μM 9599241
CV-1 Function assay Activation of peroxisome proliferator activated receptor gamma measured by induction of 50% of maximum alkaline phosphatase activity, transfection assay in CV-1 cells, EC50=0.58884μM 9836620
CV-1 Function assay Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay., EC50=0.58μM 11720854
HEK293 Function assay Agonist activity at PPARgamma expressed in HEK293 cells assessed as induction of receptor interaction with steroid receptor coactivator-1 by EYFP based reporter gene assay 16680159
HEK293 Function assay Agonist activity at PPARgamma expressed in HEK293 cells assessed as induction of receptor interaction with retinoid X-receptor alpha by EYFP based reporter gene assay 16680159
CV1 Function assay Transactivation of PPARgamma in CV1 cells, EC50=0.55μM 16821769
CHO Function assay Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay, EC50=0.14μM 20656494
COS-1 Function assay Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay, EC50=0.39μM 21130649
COS7 Function assay Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay, EC50=0.3μM 21873070
Sf21 Function assay Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake, IC50=0.3μM 21965623
Sf21 Function assay Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake, IC50=2μM 21965623
COS7 Function assay Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay, EC50=0.2μM 23130964
COS7 Function assay Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay, EC50=0.2μM 26595749
點擊查看更多細胞系數(shù)據(jù)

生物活性

產(chǎn)品描述 Pioglitazone是一種選擇性過氧化物酶體增殖物激活受體γ (PPARγ) 激動劑， 用于治療糖尿病。是全長hPPARα的弱激活劑，對全長hPPARδ沒有作用。
靶點
PPARγ [2]
體外研究(In Vitro)
體外研究活性

Pioglitazone主要被CYP2C8代謝，其次被CYP3A4代謝。[1]
實驗圖片 檢測方法 檢測指標 實驗圖片 PMID
Western blot p-VEGFR2 / VEGFR Phopsho-RB / RB 29972411
體內(nèi)研究(In Vivo)
體內(nèi)研究活性

在廣泛前壁心肌梗死小鼠中，Pioglitazone通過超聲心動圖顯著減弱左心室（LV）腔擴張和功能障礙，，以及左心室舒張末期壓力。Pioglitazone部分標準化左心房 DP/ DT（最大）和DP/ DT（最?。笫沂湛s功能，其指標在MI小鼠中顯著減少。[2]

在帕金森氏病的MPTP模型小鼠都紋狀體和黑質(zhì)致密部中，Pioglitazone導致小膠質(zhì)細胞的激活減少，減少的感應的iNOS陽性細胞和少膠質(zhì)纖維酸性蛋白陽性細胞。Pioglitazone幾乎完全阻斷TH陽性神經(jīng)元的nitrotyrosine染色，nitrotyrosine是NO介導的細胞損傷的標記物。[3]

在帕金森氏病的MPTP模型小鼠的黑質(zhì)致密部（黑質(zhì)致密部）中，Pioglitazone (約20 毫克/千克/天）衰減MPTP誘導的神經(jīng)膠質(zhì)活化，并防止多巴胺能細胞的損失。[4]

在10個月大的APPV717I轉(zhuǎn)基因小鼠的海馬和皮質(zhì)中，Pioglitazone導致活化的小膠質(zhì)細胞和活性星形細胞數(shù)量減少。Pioglitazone處理減少了促炎的表達酶環(huán)氧合酶-2（COX-2）和誘導型一氧化氮合酶（iNOS）的表達。Pioglitazone降低beta-secretase-1 (BACE1)的mRNA和蛋白質(zhì)水平，以及可溶性Abeta1-42肽的水平下降27％。[5]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05946564 Not yet recruiting
ANCA Associated Vasculitis|Rapidly Progressive Glomerulonephritis|Crescentic Glomerulonephritis
Assistance Publique - H?pitaux de Paris|Ministry of Health France
 July 2023 Phase 3
NCT05305287 Recruiting
Non-Alcoholic Fatty Liver Disease|Type 2 Diabetes|Mitochondrial Metabolism Disorders
The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 November 1 2022 Phase 4
NCT05411965 Completed
Diabetes Mellitus Type 2
Boryung Pharmaceutical Co. Ltd
 April 28 2022 Phase 1
NCT04501406 Recruiting
Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis
University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 December 15 2020 Phase 2
NCT04535700 Completed
Type 2 Diabetes
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
 September 18 2020 Phase 4
NCT00904046 Recruiting
Uric Acid Kidney Stone Disease
University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc.
 September 5 2019 Not Applicable

化學信息&溶解度

分子量 356.44 分子式

C19H20N2O3S
CAS號 111025-46-8 SDF Download Pioglitazone SDF
Smiles CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
儲存條件(自收到貨起)

體外溶解度
批次：

DMSO : 20 mg/mL ( (56.11 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計算器

體內(nèi)溶解度
批次：

現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑

 動物體內(nèi)配方計算器

實驗計算

摩爾濃度計算器

質(zhì)量 濃度 體積 分子量

動物體內(nèi)配方計算器（澄清溶液）

第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）

mg/kg g μL 只

第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項

請輸入您的姓名
請輸入您的郵箱地址 請輸入一個有效的郵箱地址
請寫點東西給我們
Tags: buy Pioglitazone | Pioglitazone ic50 | Pioglitazone price | Pioglitazone cost | Pioglitazone solubility dmso | Pioglitazone purchase | Pioglitazone manufacturer | Pioglitazone research buy | Pioglitazone order | Pioglitazone mouse | Pioglitazone chemical structure | Pioglitazone mw | Pioglitazone molecular weight | Pioglitazone datasheet | Pioglitazone supplier | Pioglitazone in vitro | Pioglitazone cell line | Pioglitazone concentration | Pioglitazone nmr
在線咨詢
聯(lián)系我們